Net profit of Sanofi India declined 7.54% to Rs 76.00 crore in the quarter ended September 2025 as against Rs 82.20 crore during the previous quarter ended September 2024. Sales declined 9.27% to Rs 475.40 crore in the quarter ended September 2025 as against Rs 524.00 crore during the previous quarter ended September 2024. ParticularsQuarter EndedSep. 2025Sep. 2024% Var. Sales475.40524.00 -9 OPM %28.2322.84 - PBDT138.70121.60 14 PBT129.60112.60 15 NP76.0082.20 -8 Powered by Capital Market - Live News

Sanofi India announced that the Board of Directors of the Company at its meeting held on 29 October 2025, has recommended a Interim Dividend of Rs.75 per share (i.e.750%), subject to the approval of the shareholders.Powered by Capital Market - Live News

The Board of Sanofi India at its meeting held on 27 October 2025 has approved the following- Appointment of Deepak Arora (DIN: 07495638) as an Additional Director of the Company with effect from 27 October 2025 and as a Managing Director (Key Managerial Personnel) of the Company for a term of 3 (three) years effective from 27 October 2025. Stepping down of Rachid Ayari as Interim Managing Director of the Company with effect from close of 26 October 2025. However, Rachid Ayari would continue to serve the Company in his role as Wholetime Director and Chief Financial Officer of the Company.Powered by Capital Market - Live News

Sanofi India will hold a meeting of the Board of Directors of the Company on 29 October 2025.Powered by Capital Market - Live News

Sanofi India announced that Surabhi Kaul, People Director - SEA&I, will cease to be a Senior Management Personnel (SMP) of the Company effective from the close of business on 14 August 2025, in view of her movement to another role within the Sanofi group. Powered by Capital Market - Live News